Targeting the p53 Pathway in Ewing Sarcoma

Table 1

TP53 Mutations in Ewings Sarcoma confirmed by DNA sequencing.

Sarcoma type	Study	Method	Exons sequenced	Mutation frequency	TP53 mutation
Ewing Sarcoma	Kovar et al., 1993 [5]	PCR-SSCP; Sequencing	4–8	2/37	C277Y, R273C
	Komuro et al., 1993 [6]	PCR-SSCP; Sequencing	5–9	2/14	152(FS), G154V
	Hamelin et al., 1994 [7]	PCR-DGGE; Sequencing	5–8	2/12	R175H, R248W
	Patiño-García and Sierrasesúmaga, 1997 [8]	PCR-DDGE; Sequencing	5–8	1/5	R273H
	Radig et al., 1998 [9]	IHC; PCR-SSCP; Sequencing	4–8	1/24	Not Specified
	Tsuchiya et al., 2000 [10]	PCR-SCCP; Sequencing	5–9	1/24	G154V
	López-Guerrero et al., 2001 [11]	Sequencing	5–8	3/19	C135F, A138D, P151R
	Park et al., 2001 [13]	PCR-SSCP; Sequencing	4–9	3/35	K132M, C135S, Q287V
	Huang et al., 2005 [12]	IHC; p53; GeneChip; Sequencing	—	8/60	W146(STOP), M160L; N239A, G244I, R248Q; R273F, A276S, R342P
	Schaefer et al., 2008 [14]	Sequencing	5–8	2/17	C141Y, R248W
Total TP53 mutations in Ewing Sarcoma					25/247 (10.1%)

DDGE: Denaturing Gradient Gel Electrophoresis; IHC: Immunohistochemistry; PCR-SSCP: Polymerase Chain Reaction Single-Strand Conformational Polymorphism; FS: Frameshift; Mutations in bold indicate p53 “hotspot mutations.’’